In conclusion, this study showed that EMPA, a highly selective SGLT2 inhibitor, and SOTA, a dual SGLT1/2 inhibitor, provide similar cardioprotective effects in a zebrafish model of DM-HFrEF. The gene discussed is SLC5A2; the disease is diabetes mellitus.